Background

Sarcoidosis is a disease characterized by heterogeneity in terms of duration and severity. Currently, there isn't biomarker with high specificity and sensitivity for sarcoidosis. However, recent studies have shown that Vanin-1 may be associated with oxidative stress, inflammation and fibrosis.

Objective

The aim of this study is to compare the serum levels of Vanin-1 between patients with sarcoidosis and healthy individuals. The study will examine the role of serum Vanin-1 levels in diagnosing the disease and determining its clinical stage.

Method

The study included 42 sarcoidosis patients and 42 healthy subjects. Vanin-1 level was analysed in addition to standard tests for diagnosis and follow-up of patients with sarcoidosis. The sensitivity and specificity of serum Vanin-1 levels for the diagnosis of sarcoidosis were evaluate dusing ROC analysis.

Results

Serum Vanin-1 levels were statistically significantly lower in the patient group compared to the control group [547.3 ng/L-1032.2 ng/L p<0.001]. When patients were classified into stages based on chest X-ray, no statistically significant differences were observed between stages in terms of serum Vanin-1 levels. The cut-off value for serum Vanin-1 level  for the diagnosis of sarcoidosis was calculated as 724.1 (AUC: 0.714, 95%) with a sensitivity of 75.5% and specificity of 62.7%.

Conclusion

This study is the first to investigate Vanin-1 levels in patients with sarcoidosis. Although our study did not show a significant difference between the radiological stages of sarcoidosis and serum Vanin-1 levels, due to the limited sample size, it is considered necessary to conduct further studies with a larger number of patients.